GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

vustanaciclib   Click here for help

GtoPdb Ligand ID: 14368

Synonyms: example 3 [US20240033264] | GDC-4198 | RGT-419B
Compound class: Synthetic organic
Comment: The chemical structure for this compound was obtained from WHO INN proposed list 134 (Feb 2026), in which it is described as a cyclin dependent kinase inhibitor with antineoplastic potential. The structure is claimed in patent US20240033264 [1], that was transferred from Regor Pharmaceuticals to Genentech (Roche). Based on this evidence vustanaciclib might be the INN for the lead CDK4/2 inhibitor RGT-419B (new code GDC-4198), that is in development for advanced/metastatic breast cancer that is insensitive to exisiting CDK4/6 inhibitors.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 9
Hydrogen bond donors 1
Rotatable bonds 6
Topological polar surface area 88.26
Molecular weight 470.57
XLogP 0.56
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CC(C)C1=C2C=C(C=CN2N=C1)C3=NC(=NC=C3)NC4=CC=C(C=N4)N5CC[C@@H](CC5=O)N(C)C
Isomeric SMILES CC(C)C1=C2C=C(C=CN2N=C1)C3=NC(=NC=C3)NC4=NC=C(C=C4)N5CC[C@@H](CC5=O)N(C)C
InChI InChI=1S/C26H30N8O/c1-17(2)21-16-29-34-12-8-18(13-23(21)34)22-7-10-27-26(30-22)31-24-6-5-20(15-28-24)33-11-9-19(32(3)4)14-25(33)35/h5-8,10,12-13,15-17,19H,9,11,14H2,1-4H3,(H,27,28,30,31)/t19-/m0/s1
InChI Key QZJWVFBTMGPBPY-IBGZPJMESA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

References
1. Hu Z, He H, Zhang F, Zhong W, Zhu X. (2024)
Cdk inhibitors.
Patent number: US20240033264A1. Assignee: Genentech Inc. Priority date: 26/09/2023. Publication date: 01/02/2024.